Reddy’s Settles On $7bn Revlimid But Natco Maintains The Lead

Alvogen Is Also In The Race To Launch US Lenalidomide In 2022

 
• By Dean Rudge
train fast run on railway track in sunny day
Natco leads the race to launch the first generic of Celgene's $7bn Revlimid • Source: Shutterstock

More from Deals

More from Business